202
Participants
Start Date
August 10, 2020
Primary Completion Date
October 3, 2023
Study Completion Date
November 10, 2023
SAR231893
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Placebo
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Investigational Site Number : 6200006, Lisbon
Investigational Site Number : 3800001, Orbassano
Investigational Site Number : 2760002, Berlin
Investigational Site Number : 8040005, Vinnytsia
Investigational Site Number : 2760006, Lübeck
Investigational Site Number : 7240001, Lugo / Lugo
Investigational Site Number : 7240005, Madrid
National Allergy and Asthma Research, LLC Site Number : 8400008, Charleston
Investigational Site Number : 2760003, Hanover
Sarasota Clinical Research Site Number : 8400012, Sarasota
Investigational Site Number : 3800005, Reggio Emilia
Allergy & Asthma Specialists, PSC Site Number : 8400004, Owensboro
Investigational Site Number : 7240002, Valencia
Investigational Site Number : 2760001, Koblenz
Investigational Site Number : 2760005, Frankfurt am Main
Investigational Site Number : 8040003, Kharkiv
The Asthma and Allergy Center Site Number : 8400010, Bellevue
OK Clinical Research LLC Site Number : 8400005, Edmond
Investigational Site Number : 8040002, Ivano-Frankivsk
Investigational Site Number : 8040006, Ivano-Frankivsk
TTS Research Site Number : 8400006, Boerne
Asthma and Allergy Associates, PC Site Number : 8400011, Colorado Springs
Southern California Institute for Respiratory Diseases Site Number : 8400009, Los Angeles
Todd Astor MD Site Number : 8400016, Culver City
Kern Allergy and Medical Research. Inc. Site Number : 8400003, Bakersfield
Allergy & Asthma Associates of Santa Clara Valley Site Number : 8400001, San Jose
Velocity Clinical Research, Medford Site Number : 8400007, Medford
Investigational Site Number : 6430001, Moscow
Investigational Site Number : 6430002, Moscow
Investigational Site Number : 6430006, Moscow
Investigational Site Number : 6430005, Moscow
Investigational Site Number : 6430007, Saint Petersburg
Investigational Site Number : 6430004, Saint Petersburg
Investigational Site Number : 0320003, CABA
Investigational Site Number : 0320001, CABA
Investigational Site Number : 0320004, Rosario
Investigational Site Number : 0320005, Rosario
Investigational Site Number : 0320002, Buenos Aires
Investigational Site Number : 1240012, Ajax
Investigational Site Number : 1240005, Toronto
Investigational Site Number : 1240009, Québec
Investigational Site Number : 1240008, Windsor
Investigational Site Number : 2760004, Leipzig
Investigational Site Number : 3800006, Monserrato
Investigational Site Number : 5280005, Arnhem
Investigational Site Number : 5280001, Breda
Investigational Site Number : 5280002, Leeuwarden
Investigational Site Number : 6200001, Aveiro
Investigational Site Number : 6200007, Guimarães
Investigational Site Number : 6200003, Matosinhos Municipality
Investigational Site Number : 6200004, Porto
Investigational Site Number : 8040008, Kyiv
Investigational Site Number : 8040007, Kyiv
Investigational Site Number : 8260001, Cambridge
Investigational Site Number : 8260002, London
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY